低分子肝素钠对慢性肺源性心脏病患者的疗效

Efficacy of low molecular weight heparin sodium in patients with chronic pulmonary heart disease

目的分析慢性肺源性心脏病应用低分子肝素钠治疗的临床效果。方法选取随州市曾都医院2019年1月至2020年1月收治的肺心病患者120例,采用随机数字表法分组,对照组60例采用常规治疗,研究组60例加用低分子肝素钠治疗,比较两组治疗后N氨基酸末端脑钠肽前体(NT-pro BNP)、肺动脉平均压(m PAP)水平、呼吸困难Brog量表(Brog)评分、1秒用力呼气容积(FEV_(1))、1秒用力呼气容积/用力肺活量(FEV_(1)/FVC)及临床疗效。结果治疗后研究组NT-pro BNP、m PAP水平低于对照组,差异有统计学意义(t=24.529,9.711,P <0.05)。治疗后研究组Brog评分低于对照组,FEV_(1)、FEV_(1)/FVC水平高于对照组,差异有统计学意义(t=8.285,3.484,6.393,P <0.05)。治疗后研究组总有效率高于对照组,差异有统计学意义(χ2=6.171,P <0.05)。结论低分子肝素钠治疗肺心病的临床疗效确切,可显著降低患者NT-pro BNP、m PAP水平,改善患者肺功能,可推广应用。

Objective To analyze the clinical efficacy of low molecular weight heparin sodium in treating chronic pulmonary heart disease(PHD). Methods A total of 120 patients with PHD admitted to Suizhou Zengdu Hospital from January 2019 to January 2020 were selected and divided into the control group and the study group according to the random number table method. The control group(n=60) was treated with conventional therapy, while the study group(n=60) was combined with low molecular weight heparin sodium. After treatment, the levels of N-amino acid terminal brain natriuretic peptide(NT-proBNP), mean pulmonary artery pressure(mPAP), Brog scale for dyspnea, forced expiratory volume in one second(FEV_(1)), forced expiratory volume in one second/forced vital capacity(FEV_(1)/FVC) and clinical efficacy were compared between the two groups. Results After treatment, the levels of NT-proBNP and mPAP in the study group were lower than those in the control group, with statistically significant differences(t=24.529, 9.711, P < 0.05). After treatment, the Brog score of the study group was lower than that of the control group, and the levels of FEV_(1) and FEV_(1)/FVC were higher than those of the control group, with statistically significant differences(t=8.285, 3.484, 6.393, P < 0.05). After treatment, the total efficacy rate of the study group was higher than that of the control group, with statistically significant difference(χ2= 6.171, P < 0.05). Conclusion Low molecular weight heparin sodium, which can significantly reduce the levels of NT-proBNP and mPAP, is effective in treating PHD. For improving the pulmonary function of patients, it can be promoted and applied.